Explore Noninvasive Rejection Monitoring in Single Lung Transplantation; A SLAM Study Overview Presented by Natera Podcast Por  arte de portada

Explore Noninvasive Rejection Monitoring in Single Lung Transplantation; A SLAM Study Overview Presented by Natera

Explore Noninvasive Rejection Monitoring in Single Lung Transplantation; A SLAM Study Overview Presented by Natera

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear a discussion on the need for noninvasive surveillance options for single lung transplantation and the role that the Prospera Lung donor derived cell free DNA (dd-cfDNA) test can play.

There are inherent, increased risks and challenges associated with management of single lung transplantation over double lung. Monitoring through invasive transbronchial biopsy procedures (TBBx) is often not the best option for these high-risk, frail patients.

In this podcast, notable transplant pulmonologists Drs. Rosenheck and Arunachalam highlight the need in the single lung population for noninvasive surveillance options. The Prospera Lung donor derived cell free DNA (dd-cfDNA) test has been validated in single and double lung transplants with emerging data in support of clinical utility. The expert speakers also discuss the recently published data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.

Justin Rosenheck, DO
Assistant Professor of Internal Medicine
Ohio State University | Columbus, OH USA

Ambalavanan Arunachalam, MD
Assistant Professor, Medicine (Pulmonary and Critical Care)
Northwestern Medicine | Chicago, IL USA

The content of this podcast was developed entirely by ISHLT's industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones